Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Female Reproductive SystemDRG 756-malignancy-female-reproductive-system-without-cc-mcc
    Ask Trek AI about this page

    Malignancy, Female Reproductive System without CC/MCC: Inpatient Reimbursement Overview

    DRG 756 encompasses inpatient stays for female reproductive system malignancies without Complication or Comorbidity or Major Complication or Comorbidity, focusing on cases with lower documented clinical complexity. Accurate coding of primary and secondary diagnoses and procedures is essential because the Diagnosis-Related Group assignment drives Medicare inpatient reimbursement and impacts hospital case-mix classification.

    Customize your policy alerts

    Sign up for drg 756 policy alerts

    Get alerted when payer policies referencing 756 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 756 Overview

    DRG 756 covers hospital admissions for malignancies of the female reproductive system without a Complication or Comorbidity and without a Major Complication or Comorbidity. This Diagnosis-Related Group includes primary surgical and medical management of gynecologic cancers when the inpatient record lacks qualifying secondary diagnoses that would elevate severity. It matters for Medicare payment because assigned Diagnosis-Related Group determines prospective reimbursement amounts and influences hospital resource use classification for these cancer admissions.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Neoadjuvant versus upfront surgery comparative effectiveness studies: Trials comparing preoperative (neoadjuvant) chemotherapy or chemoradiation strategies to immediate primary surgical management for women with localized gynecologic malignancies (e.g., high-grade endometrial, cervical, or early ovarian cancers) evaluate tumor response, surgical morbidity, and rate of complete cytoreduction. The patient population typically includes operable stage II–III disease or patients with bulky primary tumors where downsizing may improve resectability. Results inform surgeons, oncologists, and payers about resource utilization, length of stay, readmission risk, and whether preoperative therapy reduces extensive intraoperative procedures and overall inpatient costs for this DRG.
    • Perioperative enhanced recovery and morbidity-reduction intervention trials: Randomized or pragmatic studies testing multimodal enhanced recovery protocols, blood-conservation strategies, minimally invasive versus open surgical approaches, and optimized perioperative analgesia in women undergoing surgery for gynecologic malignancies. These studies enroll patients scheduled for hysterectomy, salpingo-oophorectomy, or cytoreductive procedures without major comorbid complications and measure outcomes like postoperative complications, ICU transfers, transfusion needs, and inpatient length of stay. Findings are directly relevant to providers and payers because reductions in complications and shorter hospitalizations decrease inpatient costs, DRG resource intensity, and potential downstream costs from readmissions.
    • Post-discharge survivorship, functional outcomes, and health services research: Cohort studies and pragmatic trials assessing recovery trajectories, quality of life, return-to-function, adjuvant therapy initiation timing, and care coordination after discharge among patients treated for female reproductive malignancies without major complications. Populations include patients discharged after index hospitalization who may require outpatient chemotherapy, radiation, or rehabilitation, with evaluation of factors predicting delayed adjuvant therapy, emergency department visits, and unplanned readmissions. This research guides payers and health systems on transitional care models, outpatient resource allocation, and interventions that can reduce costly post-discharge utilization associated with this DRG.

    Related Codes

    734-PELVIC-EVISCERATION-RADICAL-HYSTERECTOMY-AND-RADICAL-VULVECTOMY-WITH-CC-MCC

    Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy with CC/MCC: Inpatient Reimbursement Overview

    735-PELVIC-EVISCERATION-RADICAL-HYSTERECTOMY-AND-RADICAL-VULVECTOMY-WITHOUT-CC-MCC

    Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy: Inpatient Reimbursement Overview

    736-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITH-MCC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with MCC: Inpatient Reimbursement Overview

    737-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITH-CC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with CC: Inpatient Reimbursement Overview

    738-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy without CC/MCC: Inpatient Reimbursement Overview

    739-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITH-MCC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with MCC: Inpatient Reimbursement Overview

    740-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITH-CC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with CC: Inpatient Reimbursement Overview

    741-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy without CC/MCC: Inpatient Reimbursement Overview

    742-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-MALIGNANCY-WITH-CC-MCC

    Uterine and Adnexa Procedures for Non-Malignancy with CC/MCC: Inpatient Reimbursement Overview

    743-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Non-Malignancy without CC/MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 24

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.